This inventor holds 5 USPTO granted patents and 6 published patent applications and 2 EPO patents. Top assignees: National Institute of Health and Medical Research, Ecole Des Hautes Etudes En Sante Publique (Ehesp), Universitë De Bordeaux. Active years: 2017-2024.
Company Filing History:
5 out of 1,853 
3 out of 4 
3 out of 226 
Years Active: 2017-2024
Title: Patrick Legembre: Innovator in Reducing CD95-Mediated Cell Motility
Introduction
Patrick Legembre is a notable inventor based in Rennes, France. He has made significant contributions to the field of pharmaceuticals, particularly in the area of reducing CD95-mediated cell motility. With a total of five patents to his name, Legembre's work has the potential to impact cancer treatment and autoimmune diseases.
Latest Patents
Legembre's latest patents include innovative compounds and pharmaceutical compositions aimed at reducing CD95-mediated cell motility. One of his key inventions focuses on compounds that disrupt the CD95/PLCγ1 interaction, which is crucial for neutralizing the CD95-mediated calcium signaling pathway. This invention is particularly relevant for treating B-cell tumors and autoimmune inflammatory diseases such as systemic lupus erythematosus. Another patent involves polypeptides that also target CD95-mediated cell motility, showcasing his commitment to advancing medical science.
Career Highlights
Throughout his career, Patrick Legembre has worked with esteemed institutions such as the National Institute of Health and Medical Research and the School of Advanced Public Health. His experience in these organizations has allowed him to develop groundbreaking solutions in the medical field.
Collaborations
Legembre has collaborated with notable colleagues, including Pierre Vacher and Pierre Van De Weghe. These partnerships have contributed to the advancement of his research and the successful development of his patents.
Conclusion
Patrick Legembre is a distinguished inventor whose work in reducing CD95-mediated cell motility holds promise for significant advancements in cancer treatment and autoimmune diseases. His innovative patents and collaborations reflect his dedication to improving healthcare outcomes.